I could agree with everything except the price tag. without pre dialysis approval I think you are looking at a 3 to 5 billion sale.
spillcrap, RIONA has not been on the market a year. You continue to show your
ignorance. I eMailed Customer Relations Today - - If answered - - i will post response.
blowpost probably was the lead investor gobbling up as much as jpm would give them... so they could cover their massive short position with their new shares!
i will go slow for you and the other minions. asphyxia is a binder with no benefit over th current binders... so, mgmnt says its better becuse it can lower iv iron use... but, triferic eliminates iv iron use.... so, the only benefit krapx mgmnt was spewing to sell asphyxia (which btw got them a warning label from fda) becomes moot. get it now?
That's what we're banking on.
A fully subscribed offering in exchange for enough working capital to not only see ourselves through the ckd phase III approval ,European partnership and eventual buyout.
Of course you are correct.
It's Human nature to smell the carton of spoiled milk even when you know it went bad by the expiration date on the label.
The 110 million dollar sale was completed yesterday. If Baupost purchased a lot of those shares isn't it 3 or 7 days they have to disclose an increase in there position.
I am curious because the last time it was released that they increased there position it was a great positive catalyst that gave us great upward momentum.
Thanks in advance, hoping for some good news. This sht is getting old fast.
If you want to understand the positioning of Auryxia against the competition, I suggest that you check out ANY of the company presentations for the past YEAR or so. In the latest presentations, they segment the CKD market into 3 primary segments -- new dialysis users, dialysis users that cannot tolerate existing binders, and fighting the competition. Most of the sales will come from the first two segments and it will take TIME for the doctors to become comfortable with Auryxia. This will be a long slug out to gain share. If the non CKD label extension is granted, then the pace of adoption will then really start to take off because they will not be facing the competitive headwinds.
Hope this helps,
Auryxia will compete in the U.S. with other FDA approved phosphate binders such as Renagel ® (sevelamer hydrochloride) and Renvela ® (sevelamer carbonate), both marketed by Genzyme Corporation (a wholly-owned subsidiary of Sanofi), or Genzyme, PhosLo ® (calcium acetate), marketed by Fresenius Medical Care, Fosrenol ® (lanthanum carbonate), marketed by Shire Pharmaceuticals Group plc, and Velphoro ® (sucroferric oxyhydroxide), marketed by Fresenius Medical Care North America, as well as over-the-counter calcium carbonate products such as TUMS ® and metal-based options such as aluminum and magnesium. Our strategy to compete against these existing treatments depends in part on physicians and patients accepting that Auryxia is differentiated in the marketplace versus these FDA approved phosphate binders. In addition, we may have to compete against existing treatments on price, which becomes more challenging as generic versions of these existing treatments come to market. For example, an authorized generic of Renvela ® was launched in the U.S. in April 2014 by Impax Laboratories, Inc., or Impax, under a settlement agreement with Genzyme whereby Genzyme agreed to grant Impax a license to sell a one-time allotment of a specified number of bottles of an authorized generic version of Renvela ® tablets. Impax is also pursuing approval of its pending Abbreviated New Drug Application, or ANDA, for generic Renvela ® with the FDA. In addition, a generic formulation of PhosLo ® manufactured by Roxane Laboratories, Inc. was launched in the U.S. in October 2008. In addition, upon the expiration of its core patents, generic formulations of Fosrenol ® may be launched. These generic formulations could have a further material effect on the pricing of phosphate binders.